Track market-moving stories before they get noisy

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Agilent Technologies (A - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Agilent Technologies is one of 916 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilent Technologies is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for A's full-year earnings has moved 3.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, A has returned 25.3% so far this year. Meanwhile, stocks in the Medical group have gained about 1.1% on average. As we can see, Agilent Technologies is performing better than its sector in the calendar year.

Another stock in the Medical sector, Concentra Group (CON - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 89%.

Over the past three months, Concentra Group's consensus EPS estimate for the current year has increased 8.4%. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, Agilent Technologies belongs to the Medical - Products industry, which includes 81 individual stocks and currently sits at #75 in the Zacks Industry Rank. On average, stocks in this group have lost 22.5% this year, meaning that A is performing better in terms of year-to-date returns.

In contrast, Concentra Group falls under the Medical Services industry. Currently, this industry has 70 stocks and is ranked #157. Since the beginning of the year, the industry has moved +4.3%.

Going forward, investors interested in Medical stocks should continue to pay close attention to Agilent Technologies and Concentra Group as they could maintain their solid performance.

Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) hit a new 52-week high during mid-day trading on Monday. The company traded as high as $174.77 and last traded at $174.67, with a volume of 488742 shares. The stock had previously closed at $172.79.

Wall Street Analysts Forecast Growth A number of brokerages recently weighed in on A. UBS Group initiated coverage on shares of Agilent Technologies in a report on Wednesday, September 9th. They issued a “neutral” rating and a $165.00 price target for the company. TD Cowen upped their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Citigroup increased their price objective on Agilent Technologies from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. The Goldman Sachs Group lifted their target price on Agilent Technologies from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Finally, Bank of America boosted their target price on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.33.

Read Our Latest Report on A

Agilent Technologies Stock Down 0.1% The firm’s 50-day simple moving average is $150.90 and its 200 day simple moving average is $132.35. The company has a market cap of $49.37 billion, a P/E ratio of 34.47, a PEG ratio of 2.67 and a beta of 1.24. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05. Agilent Technologies (NYSE:A – Get Free Report) last posted its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the business posted $1.37 EPS. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts forecast that Agilent Technologies, Inc. will post 6.2 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.2550 per share. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a yield of 0.6%. Agilent Technologies’s dividend payout ratio (DPR) is 20.08%.

Insider Transactions at Agilent Technologies In other news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at approximately $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows Institutional investors have recently bought and sold shares of the company. SHP Wealth Management acquired a new stake in Agilent Technologies in the fourth quarter worth $26,000. Cedar Mountain Advisors LLC acquired a new position in shares of Agilent Technologies in the 1st quarter valued at $27,000. Markowski Investments bought a new stake in shares of Agilent Technologies in the 2nd quarter valued at $27,000. MV Capital Management Inc. bought a new stake in shares of Agilent Technologies in the 4th quarter valued at $28,000. Finally, Keating Financial Advisory Services Inc. acquired a new stake in Agilent Technologies during the 2nd quarter worth $31,000. Institutional investors and hedge funds own 87.41% of the company’s stock.

Agilent Technologies Company Profile (Get Free Report)

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.

Further Reading Five stocks we like better than Agilent Technologies CarMax Just Gave Investors a Better Reason to Believe in the Turnaround CoreWeave Comes With Risks: Analysts Split on What Matters Most Bottlenecking the Future: TSMC Prices Out the Competition Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock? Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that incorporates AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module uses AI-based segmentation without requiring conventional threshold setting or parameter tuning. By incorporating the.

It has been about a month since the last earnings report for Agilent Technologies (A - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Agilent Q3 Earnings Beat Estimates on Pharma and China StrengthAgilent Technologies reported third-quarter fiscal 2026 non-GAAP earnings of $1.62 per share, up 18% year over year and beating the Zacks Consensus Estimate by 9.46%.

Revenues of $1.88 billion rose 8.1% on a reported basis and 7.3% on a core basis, surpassing the consensus mark by 2.08%.

Strength reflected broad demand across pharma and China, while the Advanced Therapeutics Division grew nearly 30%. Instrument book-to-bill remained above 1.0 for the 10th consecutive quarter, underscoring healthy equipment demand.

A's Q3 Segment PerformanceLife Sciences and Diagnostics Markets Group revenues were $746 million, up 11% on a reported basis and 10% on a core basis. The segment's operating margin expanded to 23.5% from 17.6% a year ago, aided by strong liquid chromatography demand. Biocare contributed $10 million after the acquisition closed in late June.

Agilent CrossLab Group revenues increased 6% to $786 million on a reported basis and 5% on a core basis. Its operating margin rose 100 basis points to 34.3%.

Applied Markets Group revenues climbed 7% to $346 million on both reported and core bases, while operating margin increased 310 basis points to 24.9%. CrossLab services grew at a mid-single-digit rate, while consumables increased at a high-single-digit pace across all regions.

Agilent's End-Market MomentumPharmaceutical and biotechnology revenues were $707 million on a GAAP basis. GLP-1-related revenues increased more than 70%, while pharma growth excluding the CDMO business was 9%.

Diagnostics and clinical core revenues rose 6%, supported by mid-teens companion diagnostics growth, high-single-digit genomics growth and double-digit pathology orders.

Chemicals and advanced materials core revenues grew 7%, driven by semiconductor demand, while environmental and forensics rose 5%. Food was flat, and academia and government declined 3%. New-product traction was also notable, with the 9500 Triple Quad ICP-MS order funnel exceeding $60 million and initial orders for the new flagship GC systems running at more than twice expectations.

A's Margin and Expense TrendsNon-GAAP gross margin expanded to 56.4% from 53.1% a year earlier. The quarter included about 160 basis points of benefit from tariff refunds. Excluding that benefit, gross margin was 54.9%, up 180 basis points year over year.

Research and development (R&D) expenses on a non-GAAP basis were $118 million, up 7.3% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose to $410 million, marking a 9.3% increase from the prior-year quarter.

Non-GAAP operating margin improved 320 basis points to 28.3%, including about 110 basis points from tariff refunds. Excluding refunds, operating margin was 27.2%, up 210 basis points.

Agilent's Cash Flow and Balance SheetCash and cash equivalents were $1.76 billion as of July 31, 2026, compared with $1.79 billion as of Oct. 31, 2025.

 Long-term debt increased to $3.65 billion from $3.05 billion.

Operating cash flow was $519 million in the quarter. Free cash flow was $439 million, representing a 96% conversion of non-GAAP net income.

In the third quarter of fiscal 2026, Agilent repurchased $78 million of shares and paid $72 million in dividends.

A's Q4 and Fiscal 2026 OutlookFor the fourth quarter of fiscal 2026, Agilent expects revenues of $1.98-$2.00 billion, implying reported growth of 6.4-7.4% and core growth of 5.2-6.2%. Non-GAAP earnings are projected to be in the range of $1.71-$1.74 per share. The outlook includes about $23 million of Biocare revenues and no future benefit from potential tariff refunds.

For fiscal 2026, revenues are now projected to be between $7.49 and $7.51 billion, representing reported growth of 7.8-8.1% and core growth of 5.8-6.0%. Non-GAAP earnings are expected to be $6.18-$6.21 per share, up 15 cents at the midpoint from the prior guide. Non-GAAP operating margin expansion is expected to exceed 130 basis points, including about 30 basis points from third-quarter tariff refunds. Operating cash flow is expected to be $1.6-$1.7 billion, with capital expenditures of about $450 million.

How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended upward during the past month.

VGM ScoresCurrently, Agilent has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock has a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Agilent has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

AutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryAgilent Technologies NYSE: A executives outlined continued growth momentum, driven by improving end markets, market-share gains, instrument replacement cycles and operational changes under the company’s Ignite transformation program, during a J.P. Morgan conference discussion.

Chief Executive Officer Padraig McDonnell said Ignite has evolved from a transformation initiative into an operating system for resource allocation, operations and innovation. He said Agilent’s growth has improved from roughly flat two years ago to nearly 10% to 11%, while operating margin expanded by more than 100 basis points despite tariff headwinds. Earnings per share, which declined 3% two years ago, grew 6% in 2025 and is now growing 10%, he said.

Get Agilent Technologies alerts:

China, replacement cycles support growth 3 Surging Stocks That Don’t Need the AI Boom to Keep WinningMcDonnell said China delivered broad-based strength in the fiscal third quarter, including double-digit growth in pharma and food and high-teens growth in advanced materials. The company attributed the performance both to improving conditions and to its long-standing direct presence in China, including local manufacturing, technical teams and a sizable installed base.

Although Agilent is not calling an inflection point in China, McDonnell said it expects the country to be a mid- to high-single-digit long-term growth market. He pointed to investment in pharmaceuticals, chemicals, advanced materials, semiconductors, batteries, food and environmental testing. The company recently opened an innovation center in China focused on physical automation, he said.

Gold Has Gone Sideways, But These 3 Stocks Haven’tManagement also highlighted ongoing replacement cycles in liquid chromatography, or LC, and gas chromatography, or GC. McDonnell said LC posted double-digit growth during the latest quarter and that Agilent is less than halfway through its LC replacement cycle, which the company estimates could add 200 to 300 basis points to the overall business. China represents one area where fleets are older and replacements could accelerate, he added.

Agilent estimates it is about one-quarter through its GC replacement cycle, which McDonnell said could contribute roughly 100 basis points of growth to the overall business. The company sees opportunities across chemical and energy customers, food and environmental testing, semiconductor fabs and suppliers of high-purity chemicals.

Automation and scientific intelligence McDonnell said Agilent is concentrating investment on autonomous laboratories and scientific intelligence, with artificial intelligence serving as a key enabler. He described analytical tools as the “eyes” of a laboratory, physical automation as the “hands,” and an agentic layer as the “brain” directing experiments.

According to McDonnell, AI could expand demand for testing and drug-release work as pharmaceutical customers seek to shorten clinical-trial timelines and develop more molecules. Agilent has established an autonomous lab group under Chief Technology Officer August Specht that works alongside the company’s AI organization. Management said it expects future opportunities in automation-ready instruments, physical automation, software and partnerships, as well as selective acquisitions.

Advanced therapeutics expansion remains on track Agilent’s advanced therapeutics specialty CDMO business grew 30% in the fiscal third quarter, in line with company expectations. Management expects growth to be flat in the fourth quarter due to regulatory filing timing and a comparison with growth above 40% in the prior year. Over the long term, the company expects mid-teens growth for the business.

Chief Financial Officer Adam Elinoff said Train C is expected to begin operations in spring 2027 and is 75% booked for next year. Train C is expected to take six to eight quarters to reach full capacity, while Train D is expected to come online a couple of quarters later and require another six to eight quarters to ramp. At full capacity, the two trains could roughly double revenue from the site to about $300 million, he said.

Elinoff said the CDMO customer base has become more diversified. In 2019, three customers represented 80% of demand; now, three customers account for less than 50%. In 2025, the business was 60% commercial and 40% clinical, with commercial activity increasing. Management said recent clinical-trial news had not affected its 2027 forecast and reiterated confidence in the siRNA market.

Train C’s ramp will be dilutive to margins in 2027 because of hiring and depreciation ahead of full utilization, Elinoff said. However, he said Agilent remains committed to delivering 50 to 100 basis points or more of long-term annual operating-margin expansion through Ignite-related efficiencies.

Reshoring orders and capital allocation McDonnell said Agilent has begun booking its first reshoring and onshoring orders, with five of the top 10 pharmaceutical companies placing orders. The company continues to see a $300 million opportunity from reshoring by 2030, representing about one-third of an estimated $1 billion market opportunity. Most orders so far have come from greenfield sites, with procurement generally occurring six to 18 months before a site launch, he said.

Management expects reshoring benefits to begin appearing in the first fiscal quarter and beyond. The opportunity spans LC, GC, spectroscopy, services and consumables, according to McDonnell.

On capital allocation, executives said they intend to prioritize internal innovation, strategic capacity investments and disciplined acquisitions. McDonnell cited Biocare as an example of an acquisition that expands recurring revenue and strengthens Agilent’s pathology franchise. He said the company would not pursue a transformative deal, instead focusing on targeted additions that fill technology gaps, add recurring revenue or software capabilities, and support the company’s analytical and autonomous-laboratory strategy.

About Agilent Technologies (NYSE:A)Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.

The company's offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Agilent Technologies Right Now?Before you consider Agilent Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.

While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Bank of America Corp DE purchased a new stake in Agilent Technologies, Inc. (NYSE:A – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 1,605,576 shares of the medical research company’s stock, valued at approximately $213,269,000. Bank of America Corp DE owned about 0.57% of Agilent Technologies as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Norges Bank purchased a new stake in Agilent Technologies in the fourth quarter valued at approximately $549,158,000. Bank of New York Mellon Corp grew its stake in shares of Agilent Technologies by 87.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock valued at $695,227,000 after buying an additional 2,440,360 shares during the period. Legal & General Group Plc purchased a new stake in shares of Agilent Technologies during the 2nd quarter valued at $260,101,000. Man Group plc acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth $179,257,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Agilent Technologies during the 2nd quarter worth $176,318,000.

Agilent Technologies Stock Up 2.1% Shares of NYSE:A opened at $153.46 on Thursday. The company has a market capitalization of $43.26 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 2.29 and a beta of 1.24. The company has a 50 day moving average of $144.90 and a two-hundred day moving average of $129.22. Agilent Technologies, Inc. has a 52-week low of $108.35 and a 52-week high of $163.75. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50.

Agilent Technologies (NYSE:A – Get Free Report) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The business had revenue of $1.88 billion for the quarter, compared to analysts’ expectations of $1.84 billion. During the same period in the previous year, the company posted $1.37 earnings per share. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, analysts forecast that Agilent Technologies, Inc. will post 6.2 earnings per share for the current fiscal year. Agilent Technologies Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th will be paid a $0.255 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is 20.08%.

Analyst Ratings Changes A number of brokerages recently weighed in on A. TD Cowen lifted their target price on Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Sanford C. Bernstein upped their price target on Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Bank of America raised their price objective on Agilent Technologies from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Wells Fargo & Company reduced their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Finally, Jefferies Financial Group started coverage on Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.33.

Read Our Latest Analysis on Agilent Technologies

Insider Buying and Selling In other Agilent Technologies news, Director Mikael Dolsten sold 634 shares of Agilent Technologies stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the sale, the director directly owned 4,924 shares in the company, valued at $745,395.12. The trade was a 11.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Agilent Technologies Profile (Free Report)

Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.

The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.

Featured Articles Five stocks we like better than Agilent Technologies 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Jackson’s Record Quarter Powers the Bull Case Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

-

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on October 6, 2026, to all shareholders of record as of the close of business on October 28, 2026.

The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company’s dividend program and future payment obligations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties are detailed in Agilent’s filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2026. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

More News From Agilent Technologies Inc.

Back to Newsroom

-

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference. The event is scheduled for 10 a.m. BST on Wednesday, Sept. 23, 2026, in London. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

More News From Agilent Technologies Inc.

Back to Newsroom

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Koh Boon Hwee, independent chair of the company's board of directors, retired from the board effective Sept. 4, 2026, following more than two decades of service as a director. Koh joined Agilent's board in 2003 and served as independent chair from 2017 until his retirement.He chaired the board's Executive Committee and Nominating and Corporate Governance Committee. Koh brought extensive international l.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent's ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.

Did you analyze how Agilent Technologies (A - Free Report) fared in its international operations for the quarter ending July 2026? Given the widespread global presence of this scientific instrument maker, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.

Upon examining A's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

The company's total revenue for the quarter amounted to $1.88 billion, marking an increase of 8.1% from the year-ago quarter. We will next turn our attention to dissecting A's international revenue to get a clearer picture of how significant its operations are outside its main base.

A Closer Look at A's Revenue Streams AbroadOf the total revenue, $504 million came from Europe during the last fiscal quarter, accounting for 26.8%. This represented a surprise of -3.24% as analysts had expected the region to contribute $520.85 million to the total revenue. In comparison, the region contributed $518 million, or 28.2%, and $492 million, or 28.3%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Asia Pacific contributed $613 million in revenue, making up 32.6% of the total revenue. When compared to the consensus estimate of $594.26 million, this meant a surprise of +3.15%. Looking back, Asia Pacific contributed $553 million, or 30.1%, in the previous quarter, and $563 million, or 32.4%, in the same quarter of the previous year.

Revenue Forecasts for the International MarketsWall Street analysts expect Agilent to report $1.97 billion in total revenue for the current fiscal quarter, indicating an increase of 6.1% from the year-ago quarter. Europe and Asia Pacific are expected to contribute 28.3% (translating to $559.07 million), and 32.2% ($634.79 million) to the total revenue, respectively.

For the entire year, the company's total revenue is forecasted to be $7.46 billion, which is an improvement of 7.4% from the previous year. The revenue contributions from different regions are expected as follows: Europe will contribute 28.4% ($2.12 billion), and Asia Pacific 32% ($2.38 billion) to the total revenue.

Final ThoughtsAgilent's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

Agilent currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

A Look at Agilent Technologies' Recent Stock Price PerformanceOver the past month, the stock has gained 11.2% versus the Zacks S&P 500 composite's 3.9% increase. The Zacks Medical sector, of which Agilent is a part, has risen 1.8% over the same period. The company's shares have increased 13.6% over the past three months compared to the S&P 500's 2.2% increase. Over the same period, the sector has risen 9.2%

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core(1) compared with the third quarter of fiscal year 2025. Third-quarter GAAP net income was $362 million, or $1.28 per share. This compares with $336 million, or $1.18 per share, in the third quarter of fiscal year 2025. Non-GAAP net income(3) was $459 million (including a $17 million net.

Agilent Technologies (A - Free Report) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +9.46%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.4 per share when it actually produced earnings of $1.49, delivering a surprise of +6.43%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Agilent, which belongs to the Zacks Medical - Products industry, posted revenues of $1.88 billion for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.08%. This compares to year-ago revenues of $1.74 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Agilent shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 12.2%.

What's Next for Agilent?While Agilent has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Agilent was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.71 on $1.97 billion in revenues for the coming quarter and $6.05 on $7.45 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Medtronic (MDT - Free Report) , is yet to report results for the quarter ended July 2026. The results are expected to be released on September 1.

This medical device company is expected to post quarterly earnings of $1.39 per share in its upcoming report, which represents a year-over-year change of +10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Medtronic's revenues are expected to be $9.47 billion, up 10.4% from the year-ago quarter.

Alcoa’s Gallium Project Opens a New Door Beyond AluminumAgilent Technologies NYSE: A reported third-quarter fiscal 2026 revenue of $1.88 billion, with core revenue growth of 7.3%, exceeding the high end of its guidance range. The company said earnings per share were $1.56 excluding tariff-refund benefits, up 14% from a year earlier and $0.06 above the top of its guided range. Including a $20 million net benefit from tariff refunds, EPS was $1.62.

CEO Padraig McDonnell said the results reflected improving conditions in key markets as well as gains from the company’s Ignite Operating System, which has focused on pricing, procurement, supply-chain agility, commercial execution and operational discipline. Operating margin was 27.2% excluding the tariff-refund benefit, up 210 basis points year over year. Including the refunds, operating margin was 28.3%.

Get Agilent Technologies alerts:

Pharma, China and Applied Markets Drive Growth Gold and Bitcoin Are Rebounding—2 ETFs Give Investors a Different Kind of ExposurePharma revenue grew 12% during the quarter, led by double-digit biotech growth and mid-single-digit small-molecule growth. McDonnell said smaller and midsize biotechnology customers have begun increasing spending as funding conditions improve. Agilent’s Advanced Therapeutics division, which includes its NASD and BioVectra specialty CDMO operations, grew nearly 30%.

The company also reported more than 70% growth in GLP-1-related revenue, with contributions from both its CDMO and analytical laboratory businesses. Excluding the CDMO business, Agilent said biopharma revenue increased 9%.

3 Contrarian Trades for a Market That Looks Too HotChemicals and advanced materials grew 7%, exceeding the company’s mid-single-digit expectation. Advanced materials posted double-digit growth, supported by semiconductor-related demand for spectroscopy and vacuum tools. Environmental and forensics revenue increased 5%, while PFAS-related revenue rose 20% despite a difficult comparison period.

Diagnostics and clinical revenue grew 6%, slightly below Agilent’s expectations, but the company said underlying pathology orders rose at a double-digit rate. McDonnell said companion diagnostics grew in the mid-teens and genomics returned to high-single-digit growth. Simon May, president of the Life Sciences and Diagnostics Markets Group, said pathology order entry was strong, with a robust backlog entering the fourth quarter and continued adoption of the Dako Omnis platform.

China was a major source of upside, with revenue increasing 9% against Agilent’s prior expectation for flat growth. Growth in the region was led by double-digit pharma and food performance, as well as strength in advanced materials. McDonnell said the company saw limited benefit from government stimulus during the quarter and attributed the results to commercial execution, local capabilities and competitive wins with CXOs, pharmaceutical customers and testing laboratories.

Product Launches and Replacement Cycle Support Demand Agilent said its instrument revenue grew at a high-single-digit rate, with low-double-digit liquid chromatography growth and low-single-digit gas chromatography growth. The company recorded a book-to-bill ratio above one for the 10th consecutive quarter, indicating orders met or exceeded revenue.

McDonnell cited demand tied to liquid and gas chromatography replacement cycles, including customer upgrades to the Infinity III LC platform. He also highlighted the company’s newest product launches, including the 9500 Triple Quad ICP-MS, the 8890B and 8860B gas chromatography systems, and the Altura family of analytical columns.

The 9500 ICP-MS began shipping in late July and has already surpassed Agilent’s ramp-to-volume target, according to McDonnell. Its order funnel exceeds $60 million. Orders for the new gas chromatography systems exceeded company expectations by more than two times during their first two months of availability.

Agilent also said the number of new accounts adopting biopharma Altura columns increased 28% sequentially. The company completed its Biocare Medical acquisition in late June, and CFO Adam Elinoff said Biocare contributed $10 million in third-quarter revenue. The company expects about $23 million of Biocare revenue in the fourth quarter.

Reshoring Opportunity Begins to Produce Orders Management said pharmaceutical reshoring is beginning to create instrument and service demand. Agilent booked its initial pharma reshoring orders during the third quarter, earlier than expected, including orders from five of the world’s 10 largest pharmaceutical companies.

McDonnell reiterated the company’s estimate of a roughly $1 billion reshoring opportunity through 2030 and said Agilent expects to capture at least one-third of that opportunity. He said revenue from the trend is expected to begin building in fiscal 2027, though quarterly contributions may not be linear.

Agilent also sees opportunity from semiconductor capacity investments and AI infrastructure spending. The company said semiconductor-related demand could support advanced materials growth over the medium term, with instrument demand typically emerging 18 to 24 months after fab construction. Management noted that semiconductor manufacturing also creates longer-term PFAS testing demand.

Margins, Cash Flow and Updated Outlook Gross margin was 56.4% in the third quarter, or 54.9% excluding the net tariff-refund benefit. Elinoff said the ex-refund gross margin increased 180 basis points from the prior year due to incremental volume leverage and Ignite-related improvements.

Operating cash flow was $519 million and free cash flow was $439 million, representing a 96% conversion of non-GAAP net income. Agilent repurchased $78 million of stock and paid $72 million in dividends during the period. Following a $600 million senior-notes offering completed alongside the Biocare transaction, the company ended the quarter with net leverage of one turn.

For fiscal 2026, Agilent raised its outlook for reported revenue to $7.49 billion to $7.51 billion, representing 5.8% to 6.0% core growth. The revised midpoint is 65 basis points above its prior forecast. The company now expects full-year EPS of $6.18 to $6.21, including the third-quarter tariff-refund benefit. Excluding that benefit, it expects EPS of $6.12 to $6.15, representing 10% growth at the midpoint.

Fourth-quarter reported revenue is projected at $1.98 billion to $2.0 billion. Fourth-quarter core revenue growth is expected to be approximately 5.2% to 6.2%. Fourth-quarter EPS is forecast at $1.71 to $1.74, representing growth of 8% to 9%. The fourth-quarter outlook does not include any potential future tariff refunds. Elinoff said Agilent continues to expect $1.6 billion to $1.7 billion in operating cash flow for the full year and about $450 million in capital expenditures. He added that the company expects Ignite efficiencies to help offset inflationary pressures related to the Middle East conflict and memory-chip demand.

About Agilent Technologies (NYSE:A)Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Agilent Technologies Right Now?Before you consider Agilent Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.

While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

10.64K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in A over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Allworth Financial LP purchased a new stake in Agilent Technologies, Inc. (NYSE:A – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,420 shares of the medical research company’s stock, valued at approximately $2,712,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of A. Brighton Jones LLC increased its position in Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after buying an additional 270 shares during the period. Jones Financial Companies Lllp raised its stake in Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock worth $602,000 after acquiring an additional 769 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Agilent Technologies by 54.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 212 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after buying an additional 758 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Agilent Technologies during the second quarter worth $273,000.

Agilent Technologies Stock Performance Shares of A opened at $159.25 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The stock has a market cap of $44.98 billion, a P/E ratio of 31.98, a P/E/G ratio of 2.77 and a beta of 1.25. The business’s 50 day moving average price is $137.57 and its 200-day moving average price is $126.23. Agilent Technologies, Inc. has a 52 week low of $108.35 and a 52 week high of $160.51.

Agilent Technologies (NYSE:A – Get Free Report) last released its earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.08. The firm had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities research analysts anticipate that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth A has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Royal Bank Of Canada started coverage on Agilent Technologies in a research note on Wednesday, May 27th. They set an “outperform” rating and a $153.00 price objective on the stock. Sanford C. Bernstein started coverage on Agilent Technologies in a report on Friday, June 26th. They set an “outperform” rating and a $155.00 price target on the stock. Robert W. Baird upped their price objective on Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday, May 26th. Finally, Wells Fargo & Company decreased their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $160.24.

Read Our Latest Stock Analysis on A

Agilent Technologies Profile (Free Report)

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Further Reading Five stocks we like better than Agilent Technologies Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Wall Street analysts forecast that Agilent Technologies (A - Free Report) will report quarterly earnings of $1.48 per share in its upcoming release, pointing to a year-over-year increase of 8%. It is anticipated that revenues will amount to $1.84 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

In light of this perspective, let's dive into the average estimates of certain Agilent metrics that are commonly tracked and forecasted by Wall Street analysts.

According to the collective judgment of analysts, 'Net Revenue- Applied Markets' should come in at $336.29 million. The estimate indicates a year-over-year change of +3.8%.

Based on the collective assessment of analysts, 'Net Revenue- Agilent Crosslab Group' should arrive at $791.36 million. The estimate indicates a change of +6.4% from the prior-year quarter.

The consensus among analysts is that 'Net Revenue- Life Sciences and Diagnostics Markets Segment' will reach $712.11 million. The estimate indicates a change of +6.3% from the prior-year quarter.

View all Key Company Metrics for Agilent here>>>

Over the past month, shares of Agilent have returned +11.9% versus the Zacks S&P 500 composite's +2.8% change. Currently, A carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Advisors Capital Management LLC purchased a new position in Agilent Technologies, Inc. (NYSE:A – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 62,474 shares of the medical research company’s stock, valued at approximately $8,299,000.

Several other large investors also recently added to or reduced their stakes in A. SHP Wealth Management purchased a new stake in Agilent Technologies during the 4th quarter valued at $26,000. Core Wealth Advisors LLC bought a new stake in Agilent Technologies in the fourth quarter worth $26,000. Navalign LLC purchased a new position in Agilent Technologies during the fourth quarter worth $27,000. MV Capital Management Inc. purchased a new position in Agilent Technologies during the fourth quarter worth $28,000. Finally, Entrust Financial LLC bought a new position in Agilent Technologies during the fourth quarter valued at $31,000.

Analyst Ratings Changes A has been the subject of several analyst reports. TD Cowen raised their target price on shares of Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Jefferies Financial Group started coverage on shares of Agilent Technologies in a report on Thursday, July 9th. They set a “hold” rating and a $135.00 price target on the stock. Royal Bank Of Canada started coverage on shares of Agilent Technologies in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price objective on the stock. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $150.00 to $145.00 in a research note on Thursday, May 28th. Finally, Weiss Ratings raised Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $160.24.

Read Our Latest Stock Report on A Agilent Technologies Stock Up 0.7% NYSE:A opened at $156.50 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The stock has a market capitalization of $44.20 billion, a P/E ratio of 31.43, a P/E/G ratio of 2.75 and a beta of 1.25. The company’s 50-day simple moving average is $136.98 and its 200-day simple moving average is $126.00. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A – Get Free Report) last announced its earnings results on Wednesday, May 27th. The medical research company reported $1.49 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.08. The firm had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, equities analysts anticipate that Agilent Technologies, Inc. will post 6.03 earnings per share for the current fiscal year.

Agilent Technologies Profile (Free Report)

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Read More Five stocks we like better than Agilent Technologies 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

BIP Wealth LLC acquired a new stake in shares of Agilent Technologies, Inc. (NYSE: A) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,277 shares of the medical research company's stock, valued at approximately $834,000. Several other institutional investors have also

Agilent Technologies (NYSE: A - Get Free Report) and Many Bright Ideas Technologies (OTCMKTS:MBGNF - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides.

-

Simplifying label-free imaging analysis for more confident real-time cell analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions.

"By making advanced AI-powered image analysis accessible to more labs, we're enabling more consistent, reproducible insights that help accelerate discovery and translational research." — Knut Wintergerst, vice president and general manager, Agilent

Share Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis.

By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise.

The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research.

"The AI analysis module for xCELLigence RTCA eSight has substantially reduced the time our users spend for image analysis," said Carole Perrot, Ph.D., core facility director at Johns Hopkins All Children's Hospital. "Its automated, consistent performance across a variety of cell types and experimental conditions has improved workflow efficiency while helping ensure reproducible results. As a shared resource supporting multiple research projects, the xCELLigence is without a doubt one of our best instruments as it simplifies complex analyses and makes advanced imaging more accessible to our users."

Knut Wintergerst, vice president and general manager of the Life Sciences and Diagnostics Markets Group at Agilent, added, "With xCELLigence RTCA eSight Software 1.5.0, Agilent is bringing the same straightforward, objective analysis customers have long valued in impedance-based measurements to label-free live cell imaging. By making advanced AI-powered image analysis accessible to more labs, we’re enabling more consistent, reproducible insights that help accelerate discovery and translational research."

By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

More News From Agilent Technologies Inc.

Back to Newsroom